| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracellular Signaling Peptides and Proteins | 16 | 2020 | 281 | 1.560 |
Why?
|
| Stem Cells | 9 | 2016 | 121 | 1.270 |
Why?
|
| Intestinal Mucosa | 9 | 2015 | 197 | 1.050 |
Why?
|
| Neoplastic Stem Cells | 10 | 2020 | 141 | 0.770 |
Why?
|
| Epithelial Cells | 9 | 2016 | 248 | 0.760 |
Why?
|
| Radiation Injuries | 2 | 2016 | 52 | 0.560 |
Why?
|
| Biomarkers, Tumor | 7 | 2015 | 405 | 0.540 |
Why?
|
| Gene Deletion | 2 | 2015 | 119 | 0.540 |
Why?
|
| MicroRNAs | 9 | 2016 | 301 | 0.530 |
Why?
|
| Mice | 29 | 2020 | 4654 | 0.510 |
Why?
|
| Nerve Tissue Proteins | 8 | 2012 | 153 | 0.490 |
Why?
|
| RNA-Binding Proteins | 9 | 2014 | 86 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 540 | 0.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2020 | 138 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2020 | 465 | 0.430 |
Why?
|
| Epithelial-Mesenchymal Transition | 7 | 2017 | 115 | 0.420 |
Why?
|
| Wound Healing | 1 | 2014 | 125 | 0.410 |
Why?
|
| Intestinal Neoplasms | 2 | 2014 | 15 | 0.400 |
Why?
|
| Animals | 31 | 2020 | 10423 | 0.400 |
Why?
|
| Cell Proliferation | 13 | 2020 | 806 | 0.400 |
Why?
|
| Cell Line, Tumor | 16 | 2020 | 1319 | 0.360 |
Why?
|
| Adenocarcinoma | 7 | 2017 | 298 | 0.360 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2012 | 77 | 0.330 |
Why?
|
| Colonic Neoplasms | 5 | 2017 | 121 | 0.330 |
Why?
|
| Pancreas | 1 | 2010 | 61 | 0.330 |
Why?
|
| RNA, Messenger | 11 | 2015 | 659 | 0.320 |
Why?
|
| Mice, Nude | 9 | 2015 | 331 | 0.310 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 165 | 0.300 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2007 | 10 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2020 | 131 | 0.290 |
Why?
|
| Whole-Body Irradiation | 4 | 2016 | 40 | 0.280 |
Why?
|
| Gastrointestinal Tract | 1 | 2007 | 35 | 0.280 |
Why?
|
| Apoptosis | 10 | 2016 | 775 | 0.260 |
Why?
|
| Colon | 3 | 2015 | 121 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 1576 | 0.250 |
Why?
|
| Gene Expression Regulation | 4 | 2015 | 632 | 0.250 |
Why?
|
| Cell Cycle | 7 | 2016 | 161 | 0.250 |
Why?
|
| Alternative Splicing | 2 | 2020 | 47 | 0.240 |
Why?
|
| beta Catenin | 2 | 2020 | 66 | 0.230 |
Why?
|
| Cyclooxygenase 2 | 6 | 2016 | 68 | 0.230 |
Why?
|
| Spheroids, Cellular | 4 | 2020 | 53 | 0.230 |
Why?
|
| Intestines | 4 | 2016 | 118 | 0.230 |
Why?
|
| Microtubules | 2 | 2016 | 90 | 0.230 |
Why?
|
| Receptors, Notch | 2 | 2014 | 45 | 0.210 |
Why?
|
| Colorectal Neoplasms | 3 | 2011 | 138 | 0.210 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 16 | 0.210 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 32 | 0.210 |
Why?
|
| Cell Survival | 4 | 2017 | 409 | 0.200 |
Why?
|
| Hepacivirus | 2 | 2013 | 48 | 0.200 |
Why?
|
| Radiation-Protective Agents | 2 | 2015 | 22 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2017 | 1435 | 0.190 |
Why?
|
| DNA Damage | 2 | 2016 | 151 | 0.190 |
Why?
|
| Hepatocytes | 2 | 2020 | 80 | 0.190 |
Why?
|
| Humans | 29 | 2020 | 28097 | 0.180 |
Why?
|
| Receptor, Notch1 | 4 | 2017 | 27 | 0.180 |
Why?
|
| Biomarkers | 4 | 2016 | 765 | 0.180 |
Why?
|
| Cell Differentiation | 2 | 2015 | 407 | 0.170 |
Why?
|
| HCT116 Cells | 9 | 2011 | 53 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2016 | 288 | 0.160 |
Why?
|
| Flow Cytometry | 5 | 2016 | 289 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 328 | 0.160 |
Why?
|
| Protein Biosynthesis | 3 | 2008 | 111 | 0.150 |
Why?
|
| Mitosis | 3 | 2008 | 114 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 134 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2016 | 269 | 0.150 |
Why?
|
| Antigens, Surface | 2 | 2009 | 39 | 0.150 |
Why?
|
| Blotting, Western | 7 | 2016 | 514 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2008 | 24 | 0.140 |
Why?
|
| Enterococcus faecalis | 2 | 2008 | 71 | 0.140 |
Why?
|
| Antiviral Agents | 2 | 2016 | 112 | 0.140 |
Why?
|
| Dinoprostone | 4 | 2016 | 42 | 0.140 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 8 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 15 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 453 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 32 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Pectins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 40 | 0.120 |
Why?
|
| Dextran Sulfate | 1 | 2015 | 9 | 0.120 |
Why?
|
| Mucositis | 1 | 2015 | 7 | 0.120 |
Why?
|
| Stilbenes | 1 | 2016 | 90 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2015 | 31 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2015 | 66 | 0.120 |
Why?
|
| Pyrroles | 1 | 2015 | 36 | 0.120 |
Why?
|
| Focal Adhesions | 1 | 2015 | 15 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2015 | 36 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 25 | 0.120 |
Why?
|
| Colitis | 1 | 2015 | 54 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 149 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 13 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2015 | 123 | 0.110 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 463 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 679 | 0.110 |
Why?
|
| Benzodiazepinones | 1 | 2014 | 13 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 77 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 101 | 0.110 |
Why?
|
| RNA Interference | 4 | 2015 | 137 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.110 |
Why?
|
| Virus Replication | 1 | 2013 | 65 | 0.110 |
Why?
|
| Tumor Burden | 4 | 2015 | 110 | 0.100 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 507 | 0.100 |
Why?
|
| Gastric Mucosa | 2 | 2015 | 35 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 99 | 0.100 |
Why?
|
| Up-Regulation | 4 | 2015 | 246 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 1461 | 0.100 |
Why?
|
| Esophagus | 1 | 2012 | 70 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2008 | 44 | 0.090 |
Why?
|
| Stomach Neoplasms | 2 | 2008 | 25 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2011 | 68 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 68 | 0.090 |
Why?
|
| Inflammation | 1 | 2015 | 636 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 74 | 0.090 |
Why?
|
| Nestin | 1 | 2010 | 10 | 0.090 |
Why?
|
| 3' Untranslated Regions | 2 | 2008 | 34 | 0.080 |
Why?
|
| Protein Transport | 2 | 2007 | 158 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 21 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 55 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2010 | 137 | 0.080 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 9 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 54 | 0.080 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2009 | 51 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2016 | 578 | 0.080 |
Why?
|
| Cell Division | 1 | 2009 | 154 | 0.080 |
Why?
|
| Transfection | 4 | 2015 | 318 | 0.080 |
Why?
|
| Aegle | 1 | 2008 | 2 | 0.080 |
Why?
|
| Naphthols | 1 | 2008 | 6 | 0.080 |
Why?
|
| Aneuploidy | 1 | 2008 | 21 | 0.080 |
Why?
|
| Hemin | 1 | 2008 | 14 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 55 | 0.070 |
Why?
|
| Gastrins | 1 | 2008 | 28 | 0.070 |
Why?
|
| CELF Proteins | 4 | 2008 | 12 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2014 | 44 | 0.070 |
Why?
|
| Radiation, Ionizing | 1 | 2007 | 25 | 0.070 |
Why?
|
| Benzylidene Compounds | 1 | 2008 | 29 | 0.070 |
Why?
|
| Piperidones | 1 | 2008 | 32 | 0.070 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 72 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2011 | 287 | 0.070 |
Why?
|
| Gene Expression | 3 | 2015 | 417 | 0.070 |
Why?
|
| Regeneration | 1 | 2007 | 77 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 123 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2013 | 199 | 0.070 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 198 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 403 | 0.060 |
Why?
|
| Cell Movement | 2 | 2020 | 373 | 0.060 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 60 | 0.060 |
Why?
|
| Female | 7 | 2017 | 15156 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2020 | 119 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2015 | 520 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 276 | 0.060 |
Why?
|
| Stromal Cells | 2 | 2015 | 61 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 67 | 0.050 |
Why?
|
| Histones | 3 | 2008 | 95 | 0.050 |
Why?
|
| HT29 Cells | 3 | 2008 | 20 | 0.050 |
Why?
|
| Male | 6 | 2017 | 13491 | 0.050 |
Why?
|
| RNA Stability | 3 | 2008 | 28 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 133 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2016 | 848 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2006 | 484 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 722 | 0.050 |
Why?
|
| ras Proteins | 2 | 2014 | 43 | 0.050 |
Why?
|
| Protein Binding | 3 | 2008 | 658 | 0.050 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2013 | 20 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 257 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 42 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Mutation | 2 | 2017 | 847 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 32 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 343 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 473 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 81 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cyclin B | 2 | 2008 | 9 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2008 | 58 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2011 | 118 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2008 | 37 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2008 | 191 | 0.040 |
Why?
|
| Gamma Rays | 2 | 2008 | 27 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 179 | 0.030 |
Why?
|
| Genes, APC | 1 | 2017 | 14 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 125 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 31 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Macrophages | 2 | 2008 | 295 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 48 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 75 | 0.030 |
Why?
|
| Ceruletide | 1 | 2015 | 7 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2015 | 16 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2015 | 19 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 7 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 46 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 134 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 61 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 49 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 128 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 315 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 63 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 214 | 0.030 |
Why?
|
| Adenoma | 1 | 2014 | 61 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 30 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 120 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 478 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 152 | 0.030 |
Why?
|
| Middle Aged | 2 | 2015 | 7138 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 140 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2013 | 65 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 681 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 474 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 254 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 985 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 803 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 64 | 0.020 |
Why?
|
| Replicon | 1 | 2011 | 7 | 0.020 |
Why?
|
| Keratin-19 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Dipeptides | 1 | 2011 | 22 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2011 | 40 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Exonucleases | 1 | 2011 | 5 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vimentin | 1 | 2011 | 28 | 0.020 |
Why?
|
| Exoribonucleases | 1 | 2011 | 20 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 194 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 79 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 7740 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 490 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 78 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 151 | 0.020 |
Why?
|
| G2 Phase | 1 | 2008 | 15 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2546 | 0.020 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2008 | 3 | 0.020 |
Why?
|
| Netrin-1 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 13 | 0.020 |
Why?
|
| G1 Phase | 1 | 2008 | 17 | 0.020 |
Why?
|
| Anaphase | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 13 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 11 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 58 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 44 | 0.020 |
Why?
|
| Superoxides | 1 | 2008 | 62 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 440 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 50 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 391 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 18 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 6 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 18 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 8 | 0.020 |
Why?
|
| Tubulin | 1 | 2008 | 31 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 90 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 35 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 50 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 45 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2008 | 87 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 68 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 109 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 521 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 155 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 247 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 95 | 0.020 |
Why?
|
| ELAV Proteins | 1 | 2006 | 4 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2006 | 62 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2006 | 44 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 57 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2006 | 34 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2008 | 152 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 76 | 0.020 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2006 | 30 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2006 | 118 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 138 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 187 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 233 | 0.020 |
Why?
|
| Aged | 1 | 2015 | 5400 | 0.010 |
Why?
|